Generic Lazanda Availability

Lazanda is a brand name of fentanyl, approved by the FDA in the following formulation(s):

LAZANDA (fentanyl citrate - spray, metered;nasal)

  • Manufacturer: DEPOMED INC
    Approval date: June 30, 2011
    Strength(s): EQ 0.1MG BASE, EQ 0.4MG BASE [RLD]

Has a generic version of Lazanda been approved?

No. There is currently no therapeutically equivalent version of Lazanda available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lazanda. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Pectin compositions and methods of use for improved delivery of drugs to mucosal surfaces
    Patent 6,432,440
    Issued: August 13, 2002
    Inventor(s): Peter James; Watts & Lisbeth; Illum
    Assignee(s): West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited
    Liquid pharmaceutical compositions for administration to a mucosal surface, comprising a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions.
    Patent expiration dates:
    • April 20, 2018
      ✓ 
      Patent use: MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN
      ✓ 
      Drug product
  • Method of managing or treating pain
    Patent 8,216,604
    Issued: July 10, 2012
    Inventor(s): Watts; Peter James & Castile; Jonathan David & Lafferty; William Columbus Ian & Smith; Alan
    Assignee(s): Archimedes Development Limited
    A composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.
    Patent expiration dates:
    • October 3, 2024
      ✓ 
      Patent use: MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • June 30, 2014 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web2)